Robert F Bargatze

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Takeda Vaccines, Inc., University of California, Other. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert F Bargatze. Retrieved from https://idiyas.com/inventor/robert-f-bargatze

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 71.4

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 138(Granted Patents)

Location History:

Bozeman, MT (US) (2001 - 2017)
Cambridge, MA (US) (2023)

Company Filing History:

4 out of 72

Takeda Vaccines, Inc.

patents

2 out of 16,025

University of California

patents

1 out of 834,513

Other

patents

Years Active: 2001-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11701420 - Parenteral norovirus vaccine formulations (2023-07-18),

2. 9821049 - Method of conferring a protective immune response to Norovirus (2017-11-21),

3. 9518096 - Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity (2016-12-13),

4. 8841120 - Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity (2014-09-23),

5. 7285289 - Nanoparticle vaccines (2007-10-23),

6. 6663886 - Inhibition of cell-cell binding by lipid assemblies (2003-12-16),

7. 6235309 - Inhibition of cell-cell binding by lipid assemblies (2001-05-22),

Title: The Innovations of Robert F Bargatze

Introduction

Robert F Bargatze is a notable inventor based in Bozeman, MT (US). He has made significant contributions to the field of vaccine development, particularly in relation to Norovirus. With a total of seven patents to his name, his work has the potential to impact public health positively.

Latest Patents

Among his latest patents are innovative formulations for parenteral Norovirus vaccines. One of his inventions relates to single-dose parenteral vaccine compositions that comprise mixtures of monovalent Norovirus virus-like particles. This invention also includes methods for conferring protective immunity against Norovirus infections in human subjects. Another significant patent focuses on vaccine compositions that include Norovirus antigens and adjuvants, specifically mixtures of monovalent and multivalent virus-like particles. These inventions aim to provide effective methods for protecting individuals from Norovirus infections.

Career Highlights

Throughout his career, Robert F Bargatze has worked with prominent organizations, including Takeda Vaccines, Inc. and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field of vaccine research and development.

Collaborations

Some of his notable coworkers include Charles Richardson and Jon O Nagy. Their collaborative efforts have contributed to the advancement of vaccine technologies and methodologies.

Conclusion

Robert F Bargatze's work in vaccine innovation, particularly concerning Norovirus, showcases his dedication to improving public health through scientific research. His patents reflect a commitment to developing effective solutions for infectious diseases.

Profile summary based on public USPTO records.